Company Data
Belite Bio Inc
Ticker
BLTE
Current Price
$137.3 -4.82%
Market Cap
$5.4B
Price Target
Refer to Report
Volume
107.3K
52wk Range
$56.1 - $200
Overview
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.